why Boston Scientific Corporation [BSX] is a Good Choice for Investors After New Price Target of $43.12

Boston Scientific Corporation [NYSE: BSX] gained 0.05% or 0.02 points to close at $37.52 with a heavy trading volume of 6324557 shares. The company report on February 12, 2021 that Boston Scientific Announces February and March 2021 Conference Schedule.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.

On February 25, 2021, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa, vice president, Investor Relations, will participate in a 30-minute question-and-answer session with the host analyst at the virtual SVB Leerink 10th Annual Global Healthcare Conference. The session will begin at approximately 10:40 a.m. EST.

It opened the trading session at $37.28, the shares rose to $37.745 and dropped to $36.88, the range by which the price of stock traded the whole day. The daily chart for BSX points out that the company has recorded -4.60% loss over the past six months. However, it is still -55.68% lower than its most recent low trading price.

If we look at the average trading volume of 12.63M shares, BSX reached to a volume of 6324557 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Boston Scientific Corporation [BSX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BSX shares is $43.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BSX stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Truist have made an estimate for Boston Scientific Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 17, 2020. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Peer Perform. The new note on the price target was released on September 11, 2020, representing the official price target for Boston Scientific Corporation stock. Previously, the target price had yet another raise to $40, while SVB Leerink analysts kept a Mkt Perform rating on BSX stock. On April 01, 2020, analysts decreased their price target for BSX shares from 46 to 38.

The Average True Range (ATR) for Boston Scientific Corporation is set at 0.87, with the Price to Sales ratio for BSX stock in the period of the last 12 months amounting to 5.49. The Price to Book ratio for the last quarter was 3.45, with the Price to Cash per share for the same quarter was set at 1.39. Price to Free Cash Flow for BSX in the course of the last twelve months was 59.65 with Quick ratio for the last quarter at 1.40.

Trading performance analysis for BSX stock

Boston Scientific Corporation [BSX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.42. With this latest performance, BSX shares gained by 3.45% in over the last four-week period, additionally sinking by -4.60% over the last 6 months – not to mention a drop of -12.78% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BSX stock in for the last two-week period is set at 51.51, with the RSI for the last a single of trading hit 46.75, and the three-weeks RSI is set at 52.95 for Boston Scientific Corporation [BSX]. The present Moving Average for the last 50 days of trading for this stock 36.20, while it was recorded at 38.04 for the last single week of trading, and 37.08 for the last 200 days.

Boston Scientific Corporation [BSX]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Boston Scientific Corporation [BSX] shares currently have an operating margin of +6.90 and a Gross Margin at +65.05. Boston Scientific Corporation’s Net Margin is presently recorded at -1.41.

Boston Scientific Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.90.

Boston Scientific Corporation [BSX]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Boston Scientific Corporation posted 0.28/share EPS, while the average EPS was predicted by analysts to be reported at 0.31/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BSX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Boston Scientific Corporation go to 6.55%.

An analysis of insider ownership at Boston Scientific Corporation [BSX]

There are presently around $47,085 million, or 97.50% of BSX stock, in the hands of institutional investors. The top three institutional holders of BSX stocks are: BLACKROCK INC. with ownership of 133,511,038, which is approximately 3.614% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 110,781,158 shares of the stock with an approximate value of $4.16 billion in BSX stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $2.9 billion in BSX stock with ownership of nearly 31.849% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Boston Scientific Corporation stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 439 institutional holders increased their position in Boston Scientific Corporation [NYSE:BSX] by around 155,717,131 shares. Additionally, 387 investors decreased positions by around 196,035,833 shares, while 112 investors held positions by with 903,171,979 shares. The mentioned changes placed institutional holdings at 1,254,924,943 shares, according to the latest SEC report filing. BSX stock had 111 new institutional investments in for a total of 16,797,720 shares, while 95 institutional investors sold positions of 28,413,604 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download free eBook for 



Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.